Doses of 0.5 mg and 1 mg laquinimod also were well tolerated, with adverse events similar to placebo

The study tested HSC in 56 men with androgenetic alopecia and also was well tolerated, with no study-related adverse events reported

The study showed that the adverse event profile was as expected based on similar long-term safety studies with other extended-release opioid formulations, with the most common adverse events being nausea, constipation, vomiting and headache

The most frequently reported adverse events were dizziness, insomnia, balance disorder, headache, nausea, urinary tract infection, back pain and asthenia

The study will investigate two doses of Alpha-1 HC aerosol, an inhaled formulation of Grifols' alpha-1-proteinase inhibitor, and investigators will measure adverse events and other endpoints during the three-week study period

Started in March, the Eslicarbazepine acetate in Partial-Onset Seizures study is intended to enroll about 800 patients, with a primary endpoint of six-month retention rate and other assessments, including seizure frequency, adverse events and quality of life

No serious adverse events were reported in the primary analysis period, and no clinically meaningful differences in related adverse events were reported between the two treatment groups

No serious adverse events were reported, and there were no patient discontinuations

The study is the first of two identical trials, and the endpoints of both will include vitamin D status, adverse events, physical and clinical laboratory assessments and changes in serum calcium, serum phosphorous and plasma intact parathyroid hormone

The product had a good safety and tolerability profile, with no unexpected adverse events

The drug was generally well tolerated, and the frequency of treatment emergent adverse events was similar to placebo

Inc., of Whitehouse Station, N.J., reported data from the two-month discontinuation phase of its 12-month study showing that patients who stopped taking insomnia drug suvorexant, following daily use for one year, experienced a return of their sleeping difficulties similar to those who received placebo, while adverse events were generally consistent with those reported during the 12-month study

The drug also was well tolerated without any significant adverse events

No patients discontinued the study due to adverse events, and the incidence of adverse events and serious adverse events was similar in both the treated and placebo groups

Analysis also indicated that EV-077 was generally well tolerated, with adverse events mostly limited to increases in liver enzymes, which were transient or resolved after discontinuation

Although no patients have been exposed to IDX19368 yet, the agency took the precautionary step because of concerns related to serious cardiac-related adverse events reported for HCV patients treated with BMS-986094, a nucleotide polymerase inhibitor previously under development by Bristol-Myers Squibb Co. (BMS), of New York

Analysis also indicated that EV-077 was generally well tolerated, with adverse events mostly limited to increases in liver enzymes, which were transient or resolved after discontinuation

The compound was well tolerated at all doses evaluated, with no serious adverse events...Serious adverse events were lower in the enzalutamide group than in the placebo group

With nine patients treated to date in the RetinoStat trial and eight in the StarGen trial, no serious adverse events related to the compounds or their administration have occurred